Therapeutic | Brolucizumab |
Target | VEGFA |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCTASGFSLTDYYYMTWVRQAPGKGLEWVGFIDPDDDPYYATWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAGGDHNSGWGLDIWGQGTLVTVSS |
Light Chain | EIVMTQSPSTLSASVGDRVIITCQASEIIHSWLAWYQQKPGKAPKLLIYLASTLASGVPSRFSGSGSGAEFTLTISSLQPDDFATYYCQNVYLASTNGANFGQGTKLTVL |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | scFv |
Isotype | na |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2014 |
INN Year Recommended | 2015 |
Companies Involved | ESBATech, Alcon |
Conditions Approved | Wet age-related macular degeneration |
Conditions Active | Diabetic macular oedema, Retinal vein occlusion |
Conditions Discontinued | na |
Notes |